RE: Profit will be materially ahead of existing margins.22 Jun 2022 14:09
Plus, as stated, Provexis are the supplier to By Health under the terms of that agreement, therefore volumes should be substantial from the time of transfer. Win-win.
Current levels of business, and demand from the inherited clients, doesn't add more costs, as all can be outsourced. To develop further outside if the China market would require a sales force. The scale and projected costs of that will be interesting to see in future updates.